Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Canada was one of the first countries to condemn Iraq's invasion of Kuwait, and it quickly agreed to join the US-led coalition. In August 1990, Prime Minister Brian Mulroney committed the Canadian Forces to deploy a Naval Task Group. The destroyers HMCS Terra Nova and HMCS Athabaskan joined the maritime interdiction force supported by the supply ship HMCS Protecteur in Operation Friction. The Canadian Task Group led the coalition's maritime logistics forces in the Persian Gulf. A fourth ship, HMCS Huron, arrived in-theater after hostilities had ceased and was the first allied ship to visit Kuwait. Following the UN-authorized use of force against Iraq, the Canadian Forces deployed a CF-18 Hornet and CH-124 Sea King squadron with support personnel, as well as a field hospital to deal with casualties from the ground war. When the air war began, the CF-18s were integrated into the coalition force and provided air cover and attacked ground targets. This was the first time since the Korean War that the Canadian Armed Forces had participated in an offensive. The only CF-18 Hornet to record an official victory during the conflict was an aircraft involved in the beginning of the Battle of Bubiyan against the Iraqi Navy.
== Enzyme structure == Enteropeptidase is a type II transmembrane serine protease (TTSP) localized to the brush border of the duodenal and jejunal mucosa and synthesized as a zymogen, proenteropeptidase, which requires activation by duodenase or trypsin. TTSPs are synthesized as single chain zymogens with N-terminal propeptide sequences of different lengths. These enzymes are activated by cleavage at the carboxyl side of lysine or arginine residues present in a highly conserved activation motif. Once activated, TTSPs are predicted to remain membrane-bound through a conserved disulfide bond linking the pro- and catalytic domains. In the case of cattle enteropeptidase the primary translation product comprises 1035 residues with an expected mass of 114.9 kDa. The detected apparent mass of about 160 kDa is consistent with the specified carbohydrate content of 30 - 40%, with equal amounts of neutral and amino sugars. The activation cleavage site after Lys800 splits the heavy and light chains of mature cattle enteropeptidase. There are 17 potential N-linked glycosylation sites in the heavy chain and three in the light chain; most of these are conserved in other species. The heavy chain has a hydrophobic section near the N-terminus that supports the transmembrane anchor. The heavy chain influences the specificity of enteropeptidase. Native enteropeptidase is resistant to soybean trypsin inhibitor. However, the isolated light chain is subtle whether prepared by limited reduction of the natural protein or by mutagenesis and expression in COS cells.
The official language is Romanian, a Romance language (the most widely spoken of the Eastern Romance branch), which presents a consistent degree of similarity to Aromanian, Megleno-Romanian, and Istro-Romanian, but shares many features equally with the rest of the Western Romance languages, specifically Italian, French, Spanish, Portuguese, and Catalan. The Romanian alphabet contains the same 26 letters of the standard Latin alphabet, as well as five additional ones (namely ă, â, î, ț, and ș), totalling 31. Romanian is spoken as a first language by 91.55% of the entire population, while Hungarian and Vlax Romani are spoken by 6.28% and 1.20% of the population, respectively. There are also 40,861 native speakers of Ukrainian (concentrated in some compact regions near the border, where they form local majorities), 17,101 native speakers of Turkish, 15,943 native speakers of German, and 14,414 native speakers of Russian living in Romania. According to the Constitution, local councils ensure linguistic rights to all minorities. In localities with ethnic minorities of over 20%, that minority's language can be used in the public administration, justice system, and education. Foreign citizens and stateless persons who live in Romania have access to justice and education in their own language. English and French are the main foreign languages taught in schools. In 2010, the Organisation internationale de la Francophonie identified 4,756,100 French speakers in the country.
=== Imaging === Mammography is the method of choice for radiologic examination of male breast tissue in the diagnosis of gynecomastia when breast cancer is suspected on physical examination. If a mass/lump is felt during a physical exam, some features of the lump that would point to malignancy would be painless, non-movable (fixed), irregularly shaped, and skin changes. Mammography is rarely indicated for men since breast cancer is an unlikely diagnosis. If mammography is performed and does not reveal findings suggestive of breast cancer, further imaging is not typically necessary. If a tumor of the adrenal glands or the testes is thought to be responsible for the gynecomastia, ultrasound examination of these structures may be performed.
== Treatment == Disease progression may be slowed with immunosuppressives and other medications, and esophageal reflux, pulmonary hypertension and Raynaud phenomenon may benefit from symptomatic treatment. However, there is no cure for this disease as there is no cure for scleroderma in general.
Sources: en.wikipedia.org
==== Bretisilocin ==== In March 2026, bretisilocin entered European Medicines Agency's priority medicines (PRIME) scheme for major depressive disorder, while a phase 2 clinical trial was still ongoing.
== Entrances extant today == Ninety-one Guimard entrances survived until 1970. Eighty-six are still extant and protected as historical monuments; six were protected in 1965, the remainder in 1978. These include two original Type B édicules: at Porte Dauphine, on its original site and with the wall panels, and at Abbesses (moved from Hôtel de Ville in 1974). A third Type B of varying form at Châtelet is a 2000 recreation. The remainder of the preserved entrances are simple enclosures or entourages, with or without the light and sign arch. In addition, two sides of an entourage form an entryway to the headquarters building of the RATP.
Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. Oxidative stress from oxidative metabolism causes base damage, as well as strand breaks in DNA. Base damage is mostly indirect and caused by the reactive oxygen species generated, e.g., O−2 (superoxide radical), OH (hydroxyl radical) and H2O2 (hydrogen peroxide). Short-term oxidative stress is required to initiate stress response processes in plants.
=== Gallbladder and biliary risk === Semaglutide treatment is associated with an increased risk of biliary disease, specifically gallstones (cholelithiasis). While initially thought to be solely a byproduct of rapid weight loss, the exact mechanism may involve reduced gallbladder motility and changes in bile acid composition.
=== COSMIC: Identification confidence === The COSMIC confidence score assigns a confidence to CSI:FingerID structure identifications. The idea is similar to False Discovery Rates: All molecules in a large dataset are analysed using CSI:FingerID, the top-ranked hit for each molecule will be evaluated by COSMIC and the most trustworthy identifications can be selected for further analysis. COSMIC does not re-rank structure candidates of a particular molecule nor does it discard any identifications. COSMIC employs a confidence score that combines E-value estimation and a linear support vector machine (SVM) with enforced directionality. Calibration of CSI:FingerID scores is achieved using E-value estimates. Generating decoys for small molecule structures is a non-trivial task, that is why candidates in PubChem serve as a proxy for decoys here. The score distribution is modeled as a mixture distribution of log-normal distributions, and the P-value and E-value of a hit score are estimated using the kernel density estimate of PubChem candidate scores. The SVM is employed to classify whether a hit is correct, utilizing features such as the calibrated score, score differences to other candidates, the total peak intensity explained by the fragmentation tree, and the cardinality of molecular fingerprints. Learning is constrained to a linear SVM to mitigate the risk of overfitting, and the directionality of features is enforced. This involves making upfront decisions about whether high or low values of a feature should enhance the confidence in an identification.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.